Logo
x

Search

Subscribe Now

Myelodysplastic syndromes

Genentech's Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

Genentech's Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Sy...

  • July 21, 2021
BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

  • February 17, 2021
Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA's Approval to MDS and CMML

Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA's Approval to MDS and CMML

  • July 20, 2020
Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation

Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation

  • January 30, 2020
Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

  • June 4, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.